胃癌患者的血清S100A6BP水平和临床意义

Study of serum S100A6BP level in patients with gastric cancer and its clinical significance

目的探讨胃癌患者的血清钙周期素结合蛋白(S100A6BP)水平及临床意义。方法利用GEPIA在线数据库分析TCGA肿瘤组织数据库和GTEx正常组织数据库中408例人胃癌组织和211例正常胃组织的S100A6BP水平,酶联免疫吸附法(ELISA)检测本院2017年1月至2019年6月收集的125例胃癌患者(胃癌组)和87例健康体检者(对照组)的血清S100A6BP水平,比较两组的血清S100A6BP水平差异并经受试者工作特征(ROC)曲线评估血清S100A6BP水平鉴别胃癌的临床效能,分析血清S100A6BP水平与胃癌临床病理特征和总生存期(OS)的关系。结果GEPIA在线分析结果显示,胃癌组织的S100A6BP中位水平为73.24,高于正常组织的26.06(P<0.05)。胃癌组的血清S100A6BP水平为(285.33±83.47)pg/ml,高于对照组的(144.20±43.53)pg/ml(t=14.241,P<0.001)。ROC曲线分析显示血清S100A6BP水平诊断胃癌的曲线下面积为0.933(95%CI:0.903~0.964),取195.90 pg/ml为截断值时约登指数最大,灵敏度和特异度分别为83.20%和85.71%。胃癌患者的血清S100A6BP水平与性别、年龄、淋巴结转移、肿瘤位置和Hp感染无关(P>0.05),而与浸润深度、分化程度、肿瘤大小、组织学类型和TNM分期有关(P<0.05)。全组的中位OS为30.0(95%CI:25.906~34.094)个月,且血清S100A6BP低水平者的中位OS未达,长于高水平者的26.0(95%CI:22.894~29.106)个月(P<0.05),多因素分析发现血清S100A6BP升高是胃癌预后不良的独立因素(HR=2.135,95%CI:1.215~4.561,P=0.009)。结论胃癌患者的血清S100A6BP水平显著升高,且与恶性病理特征和不良预后有关,可作为潜在的诊断胃癌的血清肿瘤学指标。

Objective To investigate the level and clinical significance of serum calcyclin binding protein(S100A6BP)in patients with gastric cancer.Methods The S100A6BP levels of 408 cases of human gastric cancer tissues and 211 cases of human normal gastric tissues in TCGA tumor tissue database and GTEx normal tissue database were analyzed by GEPIA online database.The serum S100A6BP levels of 125 gastric cancer patients(gastric cancer group)and 87 healthy persons(control group)collected in our hospital from January 2017 to June 2019 were detected by enzyme-linked immunosorbent assay(ELISA).The difference of serum S100A6BP levels between both groups was compared,and the clinical efficacy of serum S100A6BP level in differentiating gastric cancer was evaluated by receiver operating characteristic(ROC)curve.The relationship of serum S100A6BP level with clinicopathological characteristics and overall survival(OS)of gastric cancer was analyzed.Results The results of GEPIA online analysis showed that the median S100A6BP level in gastric cancer tissues was 73.24,higher than 26.06 in normal tissues(P<0.05).The serum S100A6BP level of gastric cancer group was(285.33±83.47)pg/ml,higher than(144.20±43.53)pg/ml of control group(t=14.241,P<0.001).ROC curve analysis showed that the area-under-the-curve of serum S100A6BP level in the diagnosis of gastric cancer was 0.933(95%CI:0.903-0.964).When the cutoff value was 195.90 pg/ml,the Youden index was the highest with the sensitivity of 83.20%and specificity of 85.71%.Univariate analysis showed that serum S100A6BP level was not correlated with gender,age,lymph node metastasis,tumor location and Hp infection(P>0.05),but correlated with invasion depth,differentiation degree,tumor size,histological type and TNM stage(P<0.05).The whole median OS was 30.0(95%CI:25.906-34.094)months.Further analysis showed that the median OS of patients with low serum S100A6BP level was not reached,longer than 26.0(95%CI:22.894-29.106)months of patients with high serum S100A6BP level(P<0.05).Multivariate analysis showed that serum S100A6BP elevation was an independent factor for poor prognosis of gastric cancer(HR=2.135,95%CI:1.215-4.561,P=0.009).Conclusion The serum level of S100A6BP in patients with gastric cancer is significantly increased,which is related to the malignant pathological characteristics and poor prognosis.It can be used as a potential serum oncology index for the diagnosis of gastric cancer.